Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Inverness Medical Innovation - IMA -- Ignore unavailable to you. Want to Upgrade?

To: PuddleGlum who wrote (30)	6/11/2003 2:12:37 AM
From: Crossy	Respond to of 40

PG - IMHO this market is not really extended. The 1600 on the NAZ means to me that we got plenty of room to move up from here. I wouldn't be surprised if we see 2000 this year.. On IMA I loved their "litiagation strategy". They pushed for the "easy win". Their arrangement in essence just locks out the prior supplier to Pfizer (a japanese firm) to be replaced with IMA's Unipath subsidiary. Nice future cashflow stream for IMA (at least 5 years) - patent security for Pfizer. The japanese 3rd party supplier loses out. I guess neither IMA nor Pfizer really cares <g> rgrds CROSSY